immunotherapies

Addition of the Rhamnose (6-Deoxy-L-mannose)-rich polysaccharide, RROP-1, to normal human dermal fibroblasts (NHDFs) and human endothelial cells produced a dose-dependent stimulation of the calcium-signaling pathway, inducing fast and transient increases in Ca2 influx and intracellular free Ca2 level.

Rhamnose monohydrate (L-(+)-Rhamnose Monohydrate) is a naturally-occurring deoxy sugar that is found primarily in plants and some bacteria.

SS47, a PROTAC-based HPK1 degrader, induces proteasome-mediated HPK1 degradation and significantly enhances the in vivo antitumor efficacy of BCMA CAR-T cell research. HPK1, an immunosuppressive regulatory kinase, is a promising target for cancer immunotherapies [1].

Atorolimumab (P3x22914G4), a monoclonal antibody, is employed in immunotherapies that target the programmed death-1 (PD-1) receptor [1].

Anti-CD59 Antibody is a humanized monoclonal antibody targeting CD59 (Protectin/MAC-IP). CD59 is a GPI-anchored complement regulatory protein widely expressed on cell surfaces. It protects host cells from complement-mediated lysis by binding to complement components C8 and C9, thereby preventing the final assembly of the Membrane Attack Complex (MAC/C5b-9). CD59 is often overexpressed in various solid tumors and hematologic malignancies, enabling tumor cells to evade immune surveillance. This antibody specifically binds to CD59, blocking its inhibition of MAC assembly to restore tumor cell sensitivity to complement and induce potent Complement-Dependent Cytotoxicity (CDC). It serves as a critical tool for investigating tumor immune evasion and developing enhanced complement-based immunotherapies.

Anti-MICB Antibody is a humanized monoclonal antibody targeting MHC class I polypeptide-related sequence B (MICB). MICB is a critical ligand for the activating receptor NKG2D expressed on NK cells and CD8+ T cells. Tumor cells often evade immune surveillance by proteolytically shedding MICB via proteases (e.g., ADAM10/17), leading to reduced surface ligand density. This antibody typically binds to the α3 domain of MICB, specifically inhibiting its proteolytic shedding and stabilizing MICB expression on the tumor cell surface. This process restores NKG2D-mediated immune recognition and enhances the cytotoxic activity of NK cells and T cells against tumors, serving as a vital tool for researching tumor immune evasion mechanisms and developing novel immunotherapies.

Anti-KID3 Antibody is a specific monoclonal antibody targeting the KID3 antigen, which is identical to CD24. CD24 is overexpressed in various epithelial tumors and is considered a key marker for tumor progression and cancer stem cells. This antibody is widely applied in tumor diagnostics and research focused on developing novel immunotherapies by blocking CD24-mediated cell adhesion and signaling.

MAGE A4 (230-239) is a peptide sequence derived from the MAGE-A4 protein. This immunogenic epitope has the capability to activate T cells and induce cytotoxic responses against tumor cells expressing MAGE-A4. MAGE A4 (230-239) is utilized in developing next-generation T-cell-based immunotherapies.